Skip to content
Bending the Curve Trial by Trial
?

IFM 90

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

N = 200

Population
Previously untreated patients with myeloma under 65 years of age.
Design
Randomised study in 200 previously untreated patients under 65 years of age with myeloma, assigned at diagnosis to conventional chemotherapy or to high-dose therapy followed by autologous bone marrow transplantation.
Arms
  • Conventional chemotherapy (control): Conventional chemotherapy (regimen not described in the abstract)
  • High-dose therapy plus autologous BMT (experimental): High-dose therapy followed by autologous bone marrow transplantation (conditioning not described in the abstract)
People
Attal M, Intergroupe Français du Myélome
Δ ORR+24 pointsΔ 60-month EFS+18 pointsΔ 60-month OS+40 points
Show the numbers
Results reported for IFM 90
EndpointAnalysisHigh-dose therapy plus autologous BMTConventional chemotherapyEffect
ORRRandomised patients (analysis population not stated in the abstract)Response rate as reported; the criteria are not given in the abstract.primaryAttal 199681%57%P<0.001Complete responses 22% versus 5% and very good partial responses 16% versus 9%. Treatment-related mortality was similar in the two groups.
EFSRandomised patients (analysis population not stated in the abstract)primaryAttal 199628% at 5 y10% at 5 yP=0.01
OSRandomised patients (analysis population not stated in the abstract)primaryAttal 199652% at 5 y12% at 5 yP=0.03
Results reported for IFM 90
EndpointAnalysisHigh-dose therapy plus autologous BMTConventional chemotherapyEffect
ORRRandomised patients (analysis population not stated in the abstract)Response rate as reported; the criteria are not given in the abstract.primaryAttal 199681%57%P<0.001Complete responses 22% versus 5% and very good partial responses 16% versus 9%. Treatment-related mortality was similar in the two groups.
EFSRandomised patients (analysis population not stated in the abstract)primaryAttal 199628% at 5 y10% at 5 yP=0.01
OSRandomised patients (analysis population not stated in the abstract)primaryAttal 199652% at 5 y12% at 5 yP=0.03
Primary publication: Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335(2):91-7. PubMedDOI

Appears in

Sources

  1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. N Engl J Med. 1996;335(2):91-7.

    PubMedDOI